COSMAX Company Analysis — Why Net Income Tripled When Operating Profit Didn’t
I had been looking into the cosmetics ODM (Original Development Manufacturing) sector when I checked COSMAX’s DART filings, and the first thing that caught my eye was that Q2 2026 revenue hit KRW 794.9 billion, an all-time quarterly record. What was even more interesting was net income. H1 2026 operating profit rose 13.0% year-over-year, while net income attributable to the controlling shareholders surged 210.7%. That gap between the operating-profit growth rate and the net-income growth rate is what sent me digging through the DART financial statements.
This company, together with Kolmar Korea, is one half of what’s called the “K-ODM” duopoly — the world’s leading pure-play cosmetics ODM. It runs production bases not only in Korea but in China, the US, Indonesia, and Thailand, and it’s now expanding into Europe as well. There are three questions I wanted to answer in this piece. First, what drove the domestic subsidiary to top KRW 500 billion in quarterly revenue for the first time ever? Second, why did net income more than triple even though the operating margin actually slipped slightly, from 9.3% to 8.6%? Third, is the US subsidiary’s first-ever profitable quarter a one-off event or a genuine structural turning point? This analysis is based on COSMAX’s 2026 semi-annual report and its 2023–2025 annual business reports filed with DART.
COSMAX Company Overview — Key Data at a Glance
| Ticker Name | COSMAX | Ticker Code | 192820 (KOSPI) |
| Industry | Cosmetics ODM (Original Development Manufacturing) — production bases in Korea, China, the US, Indonesia, and Thailand | CEO | Kyung Choi & Byung-man Lee (Co-CEOs) |
| Market Position | World’s No.1 cosmetics ODM (with Kolmar Korea, forms the “K-ODM” duopoly) | Listed On | KRX KOSPI |
| H1 2026 Revenue | KRW 1,476.92bn (YoY +21.8%) | Operating Profit | KRW 126.77bn (YoY +13.0%) |
| H1 2026 Operating Margin | 8.6% — slightly down from 9.3% a year earlier | Net Income (Controlling) | KRW 90.27bn (YoY +210.7%) |
| Q2 2026 (Standalone) Revenue | KRW 794.9bn — an all-time quarterly record | Total Assets (H1 2026-end) | KRW 2,672.15bn |
| Total Equity | KRW 710.42bn | Debt Ratio | 276.2% (reflects rising inventory and receivables) |
| Basis of Analysis | DART 2026 semi-annual report + 2023–2025 annual business reports (consolidated financial statements) | ||
COSMAX Business Structure — the World’s No.1 Cosmetics ODM, Built on Five Production Bases
COSMAX is an ODM (Original Development Manufacturing) company: it takes orders from brand owners and handles the R&D and manufacturing of cosmetics on their behalf. Because it carries no house brand of its own and instead develops and produces for a huge roster of domestic and international beauty brands, its business is tied less to the fortunes of any single brand and more to the overall growth of K-beauty and the broader indie-brand ecosystem it serves. It runs production bases in Korea, China, the US, Indonesia, and Thailand, and it is now expanding into Europe as well, reinforcing its position as the world’s leading pure-play cosmetics ODM. Together with Kolmar Korea, it holds the No.1 and No.2 spots in the global cosmetics ODM market — a pairing often referred to as “K-ODM.”
What stands out in the Q2 2026 results is that the domestic subsidiary posted revenue of KRW 518.4 billion, topping KRW 500 billion in a single quarter for the first time ever (up 23% YoY), while the US subsidiary turned a quarterly operating profit for the first time since its founding. US subsidiary revenue came in in the KRW 40 billion range, up somewhere between the high-40s and roughly 80 percent year-over-year depending on which report’s methodology you use — the exact figure varies slightly across sources, but the direction is unmistakable. The China subsidiary also posted its best-ever quarterly revenue, at KRW 194.7 billion. The fact that Korea, China, and the US all posted record or turnaround results in the same quarter shows that this isn’t a story built on strength in just one region. On top of the core ODM business, the company also runs a beauty-and-wellness business spanning into “inner beauty” health supplements through COSMAX NBT (listed separately on KOSDAQ).
COSMAX 3-Year Financial Trend — Steady Revenue Growth, and Finally a Profitable US Subsidiary
| Category | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|
| Revenue | KRW 1,777.49bn | KRW 2,166.09bn | KRW 2,398.76bn | KRW 1,476.92bn |
| Operating Profit | KRW 115.69bn | KRW 175.40bn | KRW 195.79bn | KRW 126.77bn |
| Operating Margin | 6.5% | 8.1% | 8.2% | 8.6% |
| Net Income (Controlling) | KRW 57.14bn | KRW 85.80bn | KRW 123.06bn | KRW 90.27bn |
| US Subsidiary P&L | Loss | Loss | Loss | Q2 turned profitable (first time ever) |
| YoY Operating Profit | — | +51.6% | +11.6% | +13.0% |
| Debt Ratio | 334.3% | 280.1% | 247.1% | 276.2% |
What stands out most in this table is that the operating margin only edged up from 8.2% in 2025 to 8.6% in H1 2026, yet net income keeps climbing in absolute terms. In particular, the fact that the US subsidiary posted its first-ever quarterly profit in Q2 2026 matters more for its direction than for its size. It means a subsidiary that had been dragging on the group’s domestic results for years has now started contributing alongside Korea and China as a third growth pillar. That said, the debt ratio climbing back up from 247.1% at the end of 2025 to 276.2% at the end of H1 2026 is worth a closer look, which I turn to in the balance-sheet section below.
COSMAX In-Depth Balance Sheet Analysis — Operating Cash Flow Turns Positive Alongside a 39% Jump in Inventory
| Item | End of 2025 | End of H1 2026 | Change |
|---|---|---|---|
| Total Assets | KRW 2,125.42bn | KRW 2,672.15bn | +25.7% |
| Total Equity | KRW 612.34bn | KRW 710.42bn | +16.0% |
| Total Liabilities | KRW 1,513.07bn | KRW 1,961.73bn | +29.7% |
| Debt Ratio | 247.1% | 276.2% | +29.1%p |
| Inventory | KRW 270.82bn | KRW 376.85bn | +39.2% |
| Trade Receivables | KRW 426.89bn | KRW 555.88bn | +30.2% |
| Cash and Cash Equivalents | KRW 192.28bn | KRW 336.73bn | +75.1% |
| Operating Cash Flow (H1 2026) | — | KRW 62.96bn | Turned positive from -KRW 6.48bn a year earlier |
| CAPEX (PP&E Acquisitions, H1 2026) | — | KRW 122.28bn | Already 65% of the full-year 2025 total (KRW 186.96bn), spent in just half a year |
Inventory grew 39.2% and trade receivables grew 30.2% in half a year — both faster than the 21.8% growth in revenue over the same period. That’s a fairly normal pattern for a cosmetics ODM: with dozens of brand clients each ordering many small-batch, high-mix product lines, a sudden jump in orders tends to show up first as a build in raw-material inventory and receivables. That’s part of why the debt ratio climbed back up from 247.1% to 276.2%. Still, there are signals that offset that concern. Operating cash flow swung from -KRW 6.48 billion a year earlier to a positive KRW 62.96 billion, and cash and cash equivalents grew 75.1%. Even accounting for the rise in receivables and inventory, actual cash generation is genuinely improving. That said, with CAPEX already at 65% of last year’s full-year total after just half a year — driven by the Pyeongtaek Plant 3 expansion — continued investment pressure and rising borrowing look likely to persist for a while.
COSMAX CAPEX & New Business — Pyeongtaek Plant 3 and Inner Beauty as the Next Growth Engines
The company expects annual CAPEX of roughly KRW 250 billion for the foreseeable future, driven by the Pyeongtaek Plant 3 expansion and the construction of a new Shanghai headquarters building. It has already spent KRW 122.28 billion in H1 2026 alone — nearly 65% of last year’s full-year CAPEX of KRW 186.96 billion. With the domestic subsidiary topping KRW 500 billion in quarterly revenue for the first time and both the China and US subsidiaries growing at the same time, expanding production capacity looks less like a choice than a necessity. The strategy of extending its production network into Europe to cement its position as the world’s leading pure-play cosmetics ODM is closely tied to this same CAPEX cycle.
On the new-business front, the company is clearly pushing beyond cosmetics into “inner beauty” — beauty delivered through what you eat and drink. It has rolled out liquid-form health supplements built around collagen and sodium hyaluronate, along with snack-form products featuring glutathione and vitamins, positioning itself around a “beauty and wellness convergence” pitch. This segment is run through its separately listed KOSDAQ affiliate, COSMAX NBT. Layered on top of that are customized cosmetics and beauty devices, along with beauty-tech and data-driven personalization solutions — all part of the growth direction the company has laid out publicly. Together, they suggest an ambition to move beyond contract manufacturing and toward becoming a broader technology- and data-driven beauty solutions company.
COSMAX — Why +13% Operating Profit Growth Turned Into +211% Net Income Growth
| Cause | Details | Temporary / Structural |
|---|---|---|
| ① Growing K-Beauty and Indie-Brand Demand | The domestic subsidiary topped KRW 500 billion in quarterly revenue for the first time ever (up 23% YoY), driven by combined growth in domestic sales and exports | Structural (broad-based growth across the K-beauty industry) |
| ② The US Subsidiary’s First-Ever Profitable Quarter | A US subsidiary that had run at a loss for years posted its first-ever quarterly operating profit in Q2 2026, while the China subsidiary also posted its best-ever quarterly revenue | A structural turning point (though the scale of the profit is still small, so durability needs confirming) |
| ③ A Base-Effect From Financial Costs and Derivative Valuation | In H1 2025, net income was heavily weighed down by derivative valuation losses tied to redeemable convertible preferred shares; that burden eased substantially in H1 2026, causing net income growth to far outpace operating profit growth | Largely a temporary base effect (mixed with the effect of a weak prior-year comparison) |
✅ 3 Investment Highlights
① World’s No.1 Cosmetics ODM, Record Q2 Revenue of KRW 794.9bn
Holding its position alongside Kolmar Korea as one half of the K-ODM duopoly, the company delivered a quarter in which Korea, China, and the US all posted their best-ever results at the same time.
② First-Ever Profitable US Subsidiary Plus a Record China Quarter
Overseas growth pillars that had run at a loss for years are now starting to contribute to earnings, diversifying a profit structure that had previously leaned heavily on the domestic business.
③ Operating Cash Flow Turns Positive and Net-Income Leverage Improves
Operating cash flow swung from negative a year earlier to a positive KRW 62.96 billion, and as financial costs eased, the conversion rate from operating profit to net income improved markedly.
⚠️ 3 Risks
① Rising Debt Ratio and Working-Capital Pressure
Inventory rose 39.2% and trade receivables rose 30.2% in half a year, pushing the debt ratio back up from 247.1% to 276.2%. Whether this is simply a normal consequence of revenue growth needs to keep being confirmed.
② Sustained CAPEX of Roughly KRW 250bn a Year
With large-scale investment continuing via the Pyeongtaek Plant 3 expansion and the new Shanghai headquarters building, the financial burden from the lag between investment and its payoff could grow.
③ Stagnant Operating Margin
Despite three straight years of double-digit revenue growth, the operating margin has been stuck in the low-8% range and actually dipped slightly year-over-year in H1 2026 — a possible signal of ongoing cost and competitive pressure.
My Investment Judgment After Analyzing COSMAX
What struck me most after digging into this company is that the quality of its earnings is changing, not just their scale. It has moved away from being a business heavily dependent on domestic revenue: the US subsidiary posted its first-ever profit, and the China subsidiary posted its best-ever quarter. On top of that, operating cash flow turned positive and the net-income conversion rate improved as financial costs eased. That said, the rising debt ratio from growing inventory and receivables, and an operating margin still stuck in the low 8% range, look like homework this company hasn’t fully finished yet.
My judgment is to increase my position (buying in tranches). There are two key reasons behind that. First, this quarter’s simultaneous records across Korea, China, and the US don’t look like a one-off — they come alongside what looks like a genuine structural turnaround at the US subsidiary. Second, the fact that net income growth so far outpaced operating profit growth shows the quality of earnings improving as the financial-cost burden eases. That said, continued CAPEX and a stagnant operating margin are variables I’ll factor into any valuation judgment.
Here are the triggers that would change my judgment: ① confirmation that the US subsidiary’s profitability continues into subsequent quarters and isn’t a one-off, and ② inventory, receivables, and the debt ratio continuing to expand in a way that pushes working-capital pressure beyond a manageable range. If clear signs of the latter emerge, I will stop adding to my position and move to a wait-and-see stance.
⚠️ Investment Disclaimer
This article is an individual investor’s analysis based on DART electronic disclosure filings and does not constitute investment advice.
All investment decisions must be made based on your own judgment and at your own responsibility.
Investing in stocks carries the risk of loss of principal.
References
- DART Electronic Disclosure System: https://dart.fss.or.kr
- COSMAX official website: https://www.cosmax.com
- COSMAX posts record Q2 revenue and operating profit, US subsidiary turns its first profit (Businesspost): https://www.businesspost.co.kr/BP?command=article_view&num=444490
- “K-beauty boom lifts ODM too” — COSMAX posts record quarterly results (Asia Today): https://www.asiatoday.co.kr/kn/view.php?key=20260811010003746
- Basis of analysis: DART 2026 semi-annual report + 2023–2025 annual business reports (consolidated financial statements)
